Time:
Company representatives: Øystein Soug, CEO, Dr.
Language: Norwegian
Format: Introduction + open question & answer session
Questions can also be submitted in advance to renate.birkeli@targovax.com
Please join the event 5-10 minutes prior to the start by using the number and confirmation code below:
Confirmation Code: 5795788
Norway: +47 2350 0296
Sweden: +46 (0)8 5065 3942
For further information, please contact:
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About
Activating the patient's immune system to fight cancer
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.
https://news.cision.com/targovax/r/targovax-asa--invitation-to-investor-call,c3014152
(c) 2020 Cision. All rights reserved., source